Skip to main content

CORRECTION article

Front. Immunol., 07 February 2024
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1373852
This article is part of the Research Topic Immunotherapy: Up to Date Progress in Childhood and Hematological Malignancies View all 5 articles

Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

This article is a correction to:

  1. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

    1. Read original article
gueda Molinos-Quintana*Águeda Molinos-Quintana1*Anna Alonso-Saladrigues*Anna Alonso-Saladrigues2*Blanca HerreroBlanca Herrero3Teresa Caballero-VelzquezTeresa Caballero-Velázquez4Víctor Galn-GmezVíctor Galán-Gómez5Melissa PanessoMelissa Panesso6Montserrat TorrebadellMontserrat Torrebadell2Javier Delgado-SerranoJavier Delgado-Serrano4Concepcin Prez de SotoConcepción Pérez de Soto1Anna FauraAnna Faura2Berta Gonzlez-MartínezBerta González-Martínez5Ana Castillo-RobledaAna Castillo-Robleda3Cristina Diaz-de-HerediaCristina Diaz-de-Heredia6Antonio Prez-MartínezAntonio Pérez-Martínez5Jos María Prez-HurtadoJosé María Pérez-Hurtado1Susana Rives,Susana Rives7,8Jos Antonio Prez-SimnJosé Antonio Pérez-Simón4 on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)
  • 1Pediatric Unit, Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
  • 2CAR T-cell Unit. Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB). Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain
  • 3Pediatric Hemato-Oncology Department, Peditric University Hospital del Niño Jesús, Madrid, Spain
  • 4Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
  • 5Pediatric Hemato-Oncology Department, University Hospital La Paz, Institute for Health Research (IdiPAZ), Universidad Autónoma de Madrid, Madrid, Spain
  • 6Division of Pediatric Hematology and Oncology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain
  • 7Pediatric Cancer Center Barcelona (PCCB), Institut de Recerca Sant Joan de Déu, Leukemia and Pediatric Hematology Disorders, Developmental Tumors Biology Group, Barcelona, Spain
  • 8Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red De Enfermedades Raras (CIBERER), Madrid, Spain

A Corrigendum on
Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

by Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S and Pérez-Simón JA (2024) Front. Immunol. 14:1280580. doi: 10.3389/fimmu.2023.1280580

In the published article, there was an error in the author list, and author “on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)” was erroneously excluded. The corrected author list appears below.

Águeda Molinos-Quintana1*, Anna Alonso-Saladrigues2*, Blanca Herrero3, Teresa Caballero-Velázquez4, Víctor Galán-Gómez5, Melissa Panesso6, Montserrat Torrebadell2, Javier Delgado-Serrano4, Concepción Pérez de Soto1, Anna Faura2, Berta González-Martínez5, Ana Castillo-Robleda3, Cristina Diaz-de-Heredia6, Antonio Pérez-Martínez5, José María Pérez-Hurtado1, Susana Rives7,8, José Antonio Pérez-Simón4 on behalf of Spanish Group for Bone Marrow Transplantation and Cellular therapy group (GETH-TC)

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: B cell aplasia, late B-cell recovery, pre-infusion tumor burden, CD19 CART-cells, relapsed/refractory acute lymphoblastic leukemia, tisagenlecleucel, B-cell monitoring

Citation: Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S and Pérez-Simón JA (2024) Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Front. Immunol. 15:1373852. doi: 10.3389/fimmu.2024.1373852

Received: 20 January 2024; Accepted: 25 January 2024;
Published: 07 February 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Molinos-Quintana, Alonso-Saladrigues, Herrero, Caballero-Velázquez, Galán-Gómez, Panesso, Torrebadell, Delgado-Serrano, Pérez de Soto, Faura, González-Martínez, Castillo-Robleda, Diaz-de-Heredia, Pérez-Martínez, Pérez-Hurtado, Rives and Pérez-Simón. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Águeda Molinos-Quintana, YWd1ZWRhLm1vbGlub3Muc3NwYUBqdW50YWRlYW5kYWx1Y2lhLmVz; YWd1ZWRhbW9saW5vc0Bob3RtYWlsLmNvbQ==; Anna Alonso-Saladrigues, YW5uYS5hbG9uc29Ac2pkLmVz

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.